-葡萄糖共载体2 (SGLT2) 抑制剂在心力衰竭中具有保存的喷射分数:系统性审查
Amir Saeed1,2, Bilal Younas3, Ali Rohan4
1Acute Medicine, Norfolk and Norwich University Hospital, Norwich, GBR.
Cureus
|July 22, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂显著减少心血管死亡和住院治疗心力衰竭患者的心脏衰竭与保存喷射分数 (HFpEF). 这些药物还可以改善患者报告的症状,并减缓病的进展.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭在心室填充方面存在挑战,并导致频繁的住院治疗.
- -葡萄糖共运输体2 (SGLT2) 抑制剂在心力衰竭患者中显示出心血管和的益处.
- 对SGLT2抑制剂对HFpEF结果的特定影响需要进一步调查.
研究的目的:
- 系统地审查SGLT2抑制剂对HFpEF患者临床结果的影响.
- 评估对心血管死亡,心力衰竭住院,运动能力,症状和病进展的影响.
主要方法:
- 2015年1月至2025年4月期间发表的随机对照试验 (RCT) 的系统审查.
- 在HFpEF中搜索了PubMed,Embase和Cochrane图书馆的关于empagliflozin,dapagliflozin,sotagliflozin,canagliflozin和 ertugliflozin的研究.
- 使用混合方法评估工具 (MMAT) 评估方法质量;10项研究质量高 (偏差风险低).
主要成果:
- SGLT2 抑制剂显著减少了心血管死亡和与心力衰竭相关的住院治疗.
- 患者报告的结果,特别是堪萨斯城心肌病问卷 (KCCQ) 总症状得分的改善.
- 显著的脏益处包括减少病进展和减少与心血管相关的结局.
结论:
- SGLT2 抑制剂为患有HFpEF的患者提供了相当大的心血管和脏保护益处.
- 这些药物改善了患者报告的症状,并减缓了病的进展.
- 这些发现支持使用SGLT2抑制剂作为管理HFpEF的治疗选择.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
01:26Heart Failure Drugs: Inotropic Agents
732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
01:27Glucose Transporters
24.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.2K
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305